{"protocolSection":{"identificationModule":{"nctId":"NCT00478699","orgStudyIdInfo":{"id":"GECP-SCAT"},"secondaryIdInfos":[{"id":"2007-000067-15","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Spanish Lung Cancer Group","class":"OTHER"},"briefTitle":"Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","officialTitle":"Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients","acronym":"GECP-SCAT"},"statusModule":{"statusVerifiedDate":"2024-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-06"},"primaryCompletionDateStruct":{"date":"2015-06","type":"ACTUAL"},"completionDateStruct":{"date":"2015-07","type":"ACTUAL"},"studyFirstSubmitDate":"2007-05-24","studyFirstSubmitQcDate":"2007-05-24","studyFirstPostDateStruct":{"date":"2007-05-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-05-31","resultsFirstSubmitQcDate":"2024-10-28","resultsFirstPostDateStruct":{"date":"2024-12-12","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-10-28","lastUpdatePostDateStruct":{"date":"2024-12-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spanish Lung Cancer Group","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Randomized Study of Customized Adjuvant Chemotherapy based on BRCA1 mRNA Levels in Completely Resected stages II-IIIA Non-Small-Cell Lung Cancer Patients.","detailedDescription":"Randomized, phase III, predictive pharmacogenomic, open, prospective, international, multicenter study in patients with non-small-cell lung carcinoma (NSCLC) after complete resection and with N1 or N2 involvement"},"conditionsModule":{"conditions":["Non-small-cell Lung Cancer"],"keywords":["SCAT","BRCA1","BRCA1 mRNA Levels","ADJUVANT","LUNG","GECP-SCAT"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":500,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"1 Control group","type":"ACTIVE_COMPARATOR","description":"Control group:\n\n\\*Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: Four.","interventionNames":["Drug: Docetaxel/Cisplatin control"]},{"label":"2 Experimental group","type":"EXPERIMENTAL","description":"Experimental group, according to the BRAC1 levels of the tumor tissue, will be assigned one of the following treatments:\n\n* Low expression of BRCA1 → gemcitabine 1250 mg/m2, days 1 and 8, and cisplatin 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 → docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 → docetaxel 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4.","interventionNames":["Drug: Docetaxel","Drug: Gemcitabine/Cisplatin","Drug: Docetaxel/Cisplatin"]}],"interventions":[{"type":"DRUG","name":"Docetaxel/Cisplatin control","description":"Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles","armGroupLabels":["1 Control group"],"otherNames":["Taxotere/Platinol"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel 75 mg/m2 day 1, 4 cycles","armGroupLabels":["2 Experimental group"],"otherNames":["Taxotere"]},{"type":"DRUG","name":"Gemcitabine/Cisplatin","description":"Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles","armGroupLabels":["2 Experimental group"],"otherNames":["Gemzar/Platinol"]},{"type":"DRUG","name":"Docetaxel/Cisplatin","description":"Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles","armGroupLabels":["2 Experimental group"],"otherNames":["Taxotere/Platinol"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Estimated Overall Survival","description":"To assess and compare the overall survival estimated at 5 years of both treatment groups (Control arm vs Experimental arm).\n\nOverall survival:The proportion of participants in treatment group who are still alive for a certain period of time after inclusion.","timeFrame":"5 years"}],"secondaryOutcomes":[{"measure":"Disease Free Survival","description":"To assess the disease-free survival of both treatment groups. Disease-free survival: will be calculated from the date of surgery until there is some clinical evidence of disease progression or the date of death due to the disease.","timeFrame":"5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with histological confirmation of non-small-cell lung carcinoma.\n* Complete surgical resection of the disease.\n* Tumoral tissue available for molecular analysis.\n* N1 (stage II) or N2 (stage IIIA) lymph node involvement in the study of the operative piece.\n* Men or women age 18 years or older.\n* Patients with a performance status of 2 or less according to the ECOG classification.\n* Patients with the following laboratory results: ANC \\< 1500/L, Hb \\< 10 g/dL, platelets \\<100,000/L, bilirubin \\< 1.0 mg/dL, AST and ALT \\< 1.5 upper limit of normality, creatinine clearance \\< 60 mL/min.\n* Complete recovery from surgery within 6 weeks.\n* Patients who have given written informed consent before initiating any specific study screening procedure.\n\nExclusion Criteria:\n\n* Patients who have received previously chemotherapy or radiotherapy for the study disease.\n* Impossibility of complying with chemotherapy treatment due to cultural or geographic circumstances.\n* Patients with active infection, heart disease, or any other serious disease, in the judgment of the investigator.\n* Women who are pregnant or in the period of lactation.\n* Patients with a previous diagnosis of malignant disease in the last five years except for carcinoma in situ of the uterine cervix or skin cancer other than melanoma.\n* Patients under treatment with investigational agents.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bartomeu Massutí Sureda, MD","affiliation":"Hospital General Universitario de Alicante","role":"STUDY_CHAIR"},{"name":"Jose Miguel Sanchez Torres, MD","affiliation":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","role":"STUDY_CHAIR"}],"locations":[{"facility":"Hospital de Elche","city":"Elche","state":"Alicante","zip":"03202","country":"Spain","geoPoint":{"lat":38.26218,"lon":-0.70107}},{"facility":"Ico - H. Germans Trias I Pujol","city":"Badalona","state":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Hospital D'Althaia","city":"Manresa","state":"Barcelona","zip":"08243","country":"Spain","geoPoint":{"lat":41.72815,"lon":1.82399}},{"facility":"Hospital de Mataró","city":"Mataró","state":"Barcelona","zip":"08034","country":"Spain","geoPoint":{"lat":41.54211,"lon":2.4445}},{"facility":"Hospital Provincial de Castellón","city":"Castellon","state":"Castellón","country":"Spain","geoPoint":{"lat":39.98567,"lon":-0.04935}},{"facility":"Hospital Insular de Gran Canaria","city":"Las Palmas de Gran Canaria","state":"GRAN Canaria","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Hospital Clin. Univ. Santiago de Compostela","city":"Santiago de Compostela","state":"LA Coruna","zip":"15076","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Hospital San Pedro","city":"Logroño","state":"La Rioja","zip":"26004","country":"Spain","geoPoint":{"lat":42.46615,"lon":-2.45115}},{"facility":"F.H.Alcorcon","city":"Alcorcón","state":"Madrid","zip":"28922","country":"Spain","geoPoint":{"lat":40.34582,"lon":-3.82487}},{"facility":"Hospital Severo Ochoa","city":"Leganés","state":"Madrid","zip":"28911","country":"Spain","geoPoint":{"lat":40.32718,"lon":-3.7635}},{"facility":"Hospital Central de Asturias","city":"Oviedo","state":"Principality of Asturias","country":"Spain","geoPoint":{"lat":43.36029,"lon":-5.84476}},{"facility":"Hospital de La Ribera","city":"Alzira","state":"Valencia","zip":"46600","country":"Spain","geoPoint":{"lat":39.15,"lon":-0.43333}},{"facility":"Hospital de Cruces","city":"Barakaldo","state":"Vizcaya","zip":"48903","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Hospital de Basurto","city":"Bilbao","state":"Vizcaya","country":"Spain","geoPoint":{"lat":43.26271,"lon":-2.92528}},{"facility":"H.G.U. Alicante","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital de La Santa Creu I Sant Pau","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Clínic de Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Univ. Sagrat Cor","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Instituto Universitario Dexeus","city":"Barcelona","zip":"28036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Reina Sofía","city":"Córdoba","zip":"14004","country":"Spain","geoPoint":{"lat":37.89155,"lon":-4.77275}},{"facility":"Ico-Girona (Hospital Josep Trueta)","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Hospital Virgen de Las Nieves","city":"Granada","zip":"18015","country":"Spain","geoPoint":{"lat":37.18817,"lon":-3.60667}},{"facility":"Hospital de Jaén","city":"Jaén","zip":"23007","country":"Spain","geoPoint":{"lat":37.76922,"lon":-3.79028}},{"facility":"Hospital de León","city":"León","country":"Spain","geoPoint":{"lat":42.60003,"lon":-5.57032}},{"facility":"Hospital Arnau de Vilanova","city":"Lleida","zip":"46015","country":"Spain","geoPoint":{"lat":41.61674,"lon":0.62218}},{"facility":"Hospital 12 de Octubre","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clínico San Carlos","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital de La Princesa","city":"Madrid","zip":"28006","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Md Anderson Internacional","city":"Madrid","zip":"28033","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Fundación Jiménez Díaz","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital La Paz","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Puerta de Hierro","city":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Carlos Haya","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Morales Messeguer","city":"Murcia","zip":"30008","country":"Spain","geoPoint":{"lat":37.98704,"lon":-1.13004}},{"facility":"Clínica Rotger","city":"Palma de Mallorca","zip":"07012","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Son Dureta","city":"Palma de Mallorca","zip":"07014","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Son Llátzer","city":"Palma de Mallorca","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Hospital Clinico de Salamanca","city":"Salamanca","zip":"37007","country":"Spain","geoPoint":{"lat":40.96882,"lon":-5.66388}},{"facility":"Hospital de Donostia","city":"San Sebastián","zip":"20014","country":"Spain","geoPoint":{"lat":43.56667,"lon":-5.9}},{"facility":"Instituto Oncológico de San Sebastián","city":"San Sebastián","country":"Spain","geoPoint":{"lat":43.56667,"lon":-5.9}},{"facility":"Hospital Universitario de Canarias","city":"Santa Cruz de Tenerife","country":"Spain","geoPoint":{"lat":28.46824,"lon":-16.25462}},{"facility":"H. Arnau de Vilanova","city":"Valencia","zip":"46015","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital General de Valencia","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Instituto Valenciano de Oncología","city":"Valencia","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Provincial de Zamora","city":"Zamora","zip":"49012","country":"Spain","geoPoint":{"lat":41.50633,"lon":-5.74456}},{"facility":"Hospital Lozano Blesa","city":"Zaragoza","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Hospital Miguel Servet","city":"Zaragoza","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Spanish Lung Cancer Group website","url":"http://www.gecp.org"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Screening details:\n\nExperimental arm: according to the BRAC1 levels of the tumor tissue, receive different combination of treatment.","recruitmentDetails":"The recruitment was 500 patients (intention to treat patient) in 47 centers between June 2007 and May 2013.","groups":[{"id":"FG000","title":"Control Arm","description":"Docetaxel/Cisplatin: Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: 4."},{"id":"FG001","title":"Experimental Arm","description":"Experimental group, according to the BRAC1 levels of the tumor tissue, one of the following treatments will be assigned:\n\n* Low expression of BRCA1 gemcitabine 1250 mg / m2, days 1 and 8, and cisplatin 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 docetaxel 75 mg / m2, and cisplatin 75 mg / m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 docetaxel 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"108"},{"groupId":"FG001","numSubjects":"392"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"355"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"37"}]}],"dropWithdraws":[{"type":"Inclusion Error","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Not receive study treatment","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"30"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"This analisys only include those patients validated by protocol. Patients not valid by protocol will be all those who, having given their informed consent do not receive the study treatment because of any reason and/or those patients who after treatment with chemotherapy do not have a minimum of six months of follow-up.","groups":[{"id":"BG000","title":"Control Arm","description":"Docetaxel/Cisplatin: Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: 4."},{"id":"BG001","title":"Experimental Arm","description":"Experimental group, according to the BRAC1 levels of the tumor tissue, one of the following treatments will be assigned:\n\n* Low expression of BRCA1 gemcitabine 1250 mg / m2, days 1 and 8, and cisplatin 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 docetaxel 75 mg / m2, and cisplatin 75 mg / m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 docetaxel 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"355"},{"groupId":"BG002","value":"456"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63","lowerLimit":"57","upperLimit":"68"},{"groupId":"BG001","value":"61","lowerLimit":"56","upperLimit":"68"},{"groupId":"BG002","value":"62","lowerLimit":"56","upperLimit":"68"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"96"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"281"},{"groupId":"BG002","value":"360"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"355"},{"groupId":"BG002","value":"456"}]}]}]},{"title":"Smoking habit","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Former smoker","categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"221"},{"groupId":"BG002","value":"283"}]}]},{"title":"Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"130"}]}]},{"title":"Never smoker","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"43"}]}]}]},{"title":"Histology","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinomas","categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"222"}]}]},{"title":"Squamous","categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"201"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"33"}]}]}]},{"title":"Staging T","description":"T: Tumour's Classification by Size\n\nT1= Tumour \\< 3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus T2= Tumour \\> 3 cm but \\< 7 cm or tumour\n\nT3= Tumour \\> 7 cm or one that directly invades any of the following:\n\nChest wall, diaphragm, phrenic nerve, mediastinal pleura, parietal pericardium Tumour in the main bronchus \\< 2 cm distal to the carina but without involvement of the carina. Associated atelectasis or obstructive pneumonitis of the entire lung Separate tumour nodule(s) in the same lobe","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"T1","categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"90"}]}]},{"title":"T2","categories":[{"measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"230"},{"groupId":"BG002","value":"294"}]}]},{"title":"T3","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"72"}]}]}]},{"title":"Staging N","description":"N: Nodes NX:Regional lymph nodes cannot be assessed N0:No regional lymph node metastasis N1:Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension N2:Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) N3:Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"N1","categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"277"}]}]},{"title":"N2","categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"179"}]}]}]},{"title":"Stage","description":"Staging is a classification where cancer is located, if or where it has spread and whether it's affecting other parts of the body. There are 5 stages for NSCLC (0,I-IV)\n\nStage IIA: tumor larger than 4 cm but 5 cm or less in size that hasn't spread to the nearby lymph nodes.\n\nStage IIB: tumor that is 5 cm or less in size that has spread to the lymph nodes within the lung, called the N1 lymph nodes. A stage IIB cancer can also be a tumor more than 5 cm wide that has not spread to the lymph nodes.\n\nStage III: cancer spread to the lymph nodes but haven't spread to other distant parts of the body","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"IIA","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"52"}]}]},{"title":"IIB","categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"142"},{"groupId":"BG002","value":"179"}]}]},{"title":"IIIA","categories":[{"measurements":[{"groupId":"BG000","value":"50"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"225"}]}]}]},{"title":"Treatment according to BRCA1 level","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Control: Docetaxel and Cisplatin","categories":[{"measurements":[{"groupId":"BG000","value":"101"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"101"}]}]},{"title":"Experimental: BRCA1 Low: Gemcitabine / Cisplatin","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"155"},{"groupId":"BG002","value":"155"}]}]},{"title":"Experimental BRCA1 medium: Docetaxel / Cisplatin","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"99"},{"groupId":"BG002","value":"99"}]}]},{"title":"Experimental BRCA1 High: Docetaxel","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"101"},{"groupId":"BG002","value":"101"}]}]}]},{"title":"Treatment compliance","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Completed","categories":[{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"307"},{"groupId":"BG002","value":"391"}]}]},{"title":"Not completed","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"65"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Estimated Overall Survival","description":"To assess and compare the overall survival estimated at 5 years of both treatment groups (Control arm vs Experimental arm).\n\nOverall survival:The proportion of participants in treatment group who are still alive for a certain period of time after inclusion.","populationDescription":"Only those patients validated by protocol. Patients not valid by protocol will be all those who, having given their informed consent do not receive the study treatment because of any reason and/or those patients who after treatment with chemotherapy do not have a minimum of six months of follow-up.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"proportion of participants","timeFrame":"5 years","groups":[{"id":"OG000","title":"Control Arm","description":"Docetaxel/Cisplatin: Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: 4."},{"id":"OG001","title":"Experimental Arm","description":"Experimental group, according to the BRAC1 levels of the tumor tissue, one of the following treatments will be assigned:\n\n* Low expression of BRCA1 gemcitabine 1250 mg / m2, days 1 and 8, and cisplatin 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 docetaxel 75 mg / m2, and cisplatin 75 mg / m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 docetaxel 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"355"}]}],"classes":[{"title":"Control arm vs Experimental arm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"355"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.44","upperLimit":"0.64"},{"groupId":"OG001","value":"0.56","lowerLimit":"0.51","upperLimit":"0.61"}]}]},{"title":"Control arm vs Gemcitabine /Cisplatin Experimental arm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"155"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.44","upperLimit":"0.64"},{"groupId":"OG001","value":"0.56","lowerLimit":"0.47","upperLimit":"0.64"}]}]},{"title":"Control arm vs Docetaxel /Cisplatin Experimental arm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"99"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.44","upperLimit":"0.64"},{"groupId":"OG001","value":"0.53","lowerLimit":"0.42","upperLimit":"0.62"}]}]},{"title":"Control arm vs Docetaxel Experimental Arm","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"101"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","lowerLimit":"0.44","upperLimit":"0.64"},{"groupId":"OG001","value":"0.60","lowerLimit":"0.49","upperLimit":"0.69"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Based on the relevant clinical evidence of the prognostic and predictive value of BRCA1, proposes the present study with which it is intended to demonstrate that adjuvant chemotherapy Individualized based on BRCA1 expression (Experimental arm), it is more effective than chemotherapy without individualize based (Control arm) in patients with completely resected stage II-IIIA NSCLC.","nonInferiorityType":"SUPERIORITY","pValue":"0.73","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.946","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.689","ciUpperLimit":"1.298"}]},{"type":"SECONDARY","title":"Disease Free Survival","description":"To assess the disease-free survival of both treatment groups. Disease-free survival: will be calculated from the date of surgery until there is some clinical evidence of disease progression or the date of death due to the disease.","populationDescription":"Participants are analyzed by protocol.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"80% Confidence Interval","unitOfMeasure":"Month","timeFrame":"5 years","groups":[{"id":"OG000","title":"Control Arm","description":"Docetaxel/Cisplatin: Docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both on day 1, every 21 days. Total cycles: 4."},{"id":"OG001","title":"Experimental Arm","description":"Experimental group, according to the BRAC1 levels of the tumor tissue, one of the following treatments will be assigned:\n\n* Low expression of BRCA1 gemcitabine 1250 mg / m2, days 1 and 8, and cisplatin 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 docetaxel 75 mg / m2, and cisplatin 75 mg / m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 docetaxel 75 mg / m2, day 1. Cycles every 21 days. Total cycles: 4."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"355"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.7","lowerLimit":"18.6","upperLimit":"58.8"},{"groupId":"OG001","value":"32.7","lowerLimit":"24.1","upperLimit":"41.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Control Arm v Experimental Arm","nonInferiorityType":"SUPERIORITY","pValue":"0.753","statisticalMethod":"Log Rank","paramType":"Median Difference (Final Values)","paramValue":"79.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"63.5","ciUpperLimit":"95.1"},{"groupIds":["OG000","OG001"],"groupDescription":"Control Arm v Experimental Arm","nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"The initial hyphotesis were the disease free survival were longest under 65 vs upper 65.","pValue":"0.025","statisticalMethod":"Log Rank","paramType":"Median Difference (Final Values)","paramValue":"38.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"28","ciUpperLimit":"38.7"}]}]},"adverseEventsModule":{"frequencyThreshold":".4","timeFrame":"70 month","eventGroups":[{"id":"EG000","title":"Control Group","description":"Control group\n\n\\- Docetaxel 75 mg/m2, y cisplatin 75 mg/m2, both day 1 every 21 days. Total cycles: 4.","deathsNumAffected":3,"deathsNumAtRisk":108,"seriousNumAffected":36,"seriousNumAtRisk":108,"otherNumAffected":105,"otherNumAtRisk":108},{"id":"EG001","title":"Experimental Group:All Reported Adverse Events Related to Study Medication","description":"Include participants in experimental arm\n\nExperimental group, according to the BRAC1 levels of the tumor tissue, will be assigned one of the following treatments:\n\n* Low expression of BRCA1 → gemcitabine 1250 mg/m2, days 1 and 8, and cisplatin 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4\n* Intermediate expression levels of BRCA1 → docetaxel 75 mg/m2, and cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total cycles: 4.\n* High expression levels of BRCA1 → docetaxel 75 mg/m2, day 1. Cycles every 21 days. Total cycles: 4.","deathsNumAffected":8,"deathsNumAtRisk":392,"seriousNumAffected":66,"seriousNumAtRisk":392,"otherNumAffected":384,"otherNumAtRisk":392}],"seriousEvents":[{"term":"Pulmonary thromboembolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":392}]},{"term":"Thrombolysis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":392}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":108},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":392}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":392}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":22,"numAtRisk":108},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":392}]},{"term":"Respiratory infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":392}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":108},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":392}]},{"term":"Anorexy","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":392}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":392}]},{"term":"Vomits","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":108},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":392}]},{"term":"Acute kidney failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":392}]},{"term":"Palmoplantar disease","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":108},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":392}]},{"term":"Urinary tract infection","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":392}]},{"term":"Broken arm","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":392}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":392}]}],"otherEvents":[{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":392}]},{"term":"Allergic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":108},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":392}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":32,"numAffected":32,"numAtRisk":108},{"groupId":"EG001","numEvents":266,"numAffected":266,"numAtRisk":392}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":108},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":392}]},{"term":"Abdominal pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":108},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":392}]},{"term":"Cardiac disorders","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":392}]},{"term":"Hemoglobin","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":81,"numAffected":81,"numAtRisk":108},{"groupId":"EG001","numEvents":220,"numAffected":220,"numAtRisk":392}]},{"term":"Leukocites","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":108},{"groupId":"EG001","numEvents":80,"numAffected":80,"numAtRisk":392}]},{"term":"Neutrophils","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":108},{"groupId":"EG001","numEvents":138,"numAffected":138,"numAtRisk":392}]},{"term":"Platelets","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":108},{"groupId":"EG001","numEvents":50,"numAffected":50,"numAtRisk":392}]},{"term":"Epistaxis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":108},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":392}]},{"term":"Edema","organSystem":"General disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":392}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":82,"numAtRisk":108},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":392}]},{"term":"Sensitivity in sensory processing","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":108},{"groupId":"EG001","numEvents":47,"numAffected":47,"numAtRisk":392}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":392}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":108},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":392}]},{"term":"Anorexy","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":108},{"groupId":"EG001","numEvents":63,"numAffected":63,"numAtRisk":392}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":108},{"groupId":"EG001","numEvents":57,"numAffected":57,"numAtRisk":392}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":108},{"groupId":"EG001","numEvents":110,"numAffected":110,"numAtRisk":392}]},{"term":"Mucositis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":108},{"groupId":"EG001","numEvents":93,"numAffected":93,"numAtRisk":392}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":108},{"groupId":"EG001","numEvents":180,"numAffected":180,"numAtRisk":392}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":108},{"groupId":"EG001","numEvents":126,"numAffected":126,"numAtRisk":392}]},{"term":"Epigastralgia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":108},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":392}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":142,"numAffected":142,"numAtRisk":392}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":392}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":108},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":392}]},{"term":"GGT alteration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":90,"numAtRisk":108},{"groupId":"EG001","numEvents":42,"numAffected":42,"numAtRisk":392}]},{"term":"Creatinine alteration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":108},{"groupId":"EG001","numEvents":33,"numAffected":33,"numAtRisk":392}]},{"term":"GPT/ GOT alterations","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":31,"numAffected":31,"numAtRisk":108},{"groupId":"EG001","numEvents":37,"numAffected":37,"numAtRisk":392}]},{"term":"LDH alteration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":29,"numAtRisk":108},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":392}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 10.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":35,"numAtRisk":108},{"groupId":"EG001","numEvents":51,"numAffected":51,"numAtRisk":392}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Eva Pereira","organization":"Fundación GECP","email":"epereira@gecp.org","phone":"+34 934302006"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077143","term":"Docetaxel"},{"id":"D002945","term":"Cisplatin"},{"id":"D000093542","term":"Gemcitabine"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D003841","term":"Deoxycytidine"},{"id":"D003562","term":"Cytidine"},{"id":"D011741","term":"Pyrimidine Nucleosides"},{"id":"D011743","term":"Pyrimidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"}]}},"hasResults":true}